Systematizing serendipity for cardiovascular drug discovery

Circulation

Volumn 120, Issue 3, 2009, Pages 255-263

  Schlueter, Peter J ^a   Peterson, Randall T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ASCORBIC ACID; CARDIOVASCULAR AGENT; DICOUMAROL; DIGITOXIN; EMETINE; EZETIMIBE; ISONIAZID; LOPERAMIDE; METHADONE; MOLSIDOMINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TERFENADINE;

AFFINITY CHROMATOGRAPHY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DISEASE MODEL; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EMBRYONIC STEM CELL; GENETIC SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVERTEBRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN TARGETING; REVIEW; RODENT; TUBERCULOSIS; ZEBRA FISH;

ANIMALS; CARDIOVASCULAR AGENTS; CELLS, CULTURED; DRUG DISCOVERY; HUMANS;

EID: 67651083239     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.824177     Document Type: Review

References (82)

1. Mueller RL, Scheidt S. History of drugs for thrombotic disease: discovery, development, and directions for the future. Circulation. 1994;89:432-449.
2. Norman JN. William Withering and the purple foxglove: a bicentennial tribute. J Clin Pharmacol. 1985;25:479-483.
3. Austin DH, Kile J, Moore D, Marron DB. Research and development in the pharmaceutical industry. Congressional Budget Office. 2006.
4. Brown D, Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discovery Today. 2003;8:1067-1077.
5. Fishman MC, Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature. 2005;437:491-493.
6. Drews J. Drug discovery: a historical perspective. Science. 2000;287: 1960-1964.
7. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115:e69-e171.
8. Qyang Y, Martin-Puig S, Chiravuri M, Chen S, Xu H, Bu L, Jiang X, Lin L, Granger A, Moretti A, Caron L, Wu X, Clarke J, Taketo MM, Laugwitz KL, Moon RT, Gruber P, Evans SM, Ding S, Chien KR. The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell. 2007;1:165-179.
9. Ding S, Wu TY, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A. 2003;100:7632-7637.
10. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, Lee RT. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation. 2003;107:1912-1916.
11. Sadek H, Hannack B, Choe E, Wang J, Latif S, Garry MG, Garry DJ, Longgood J, Frantz DE, Olson EN, Hsieh J, Schneider JW. Cardiogenic small molecules that enhance myocardial repair by stem cells. Proc Natl Acad Sci U S A. 2008;105:6063-6068.
12. Smith C. Tools for drug discovery: tools of the trade. Nature. 2007;446: 219-222.
13. Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett. 2002;127:279-284.
14. Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci U S A. 2004;101:2870-2875.
15. Venkatesh N, Feng Y, DeDecker B, Yacono P, Golan D, Mitchison T, McKeon F. Chemical genetics to identify NFAT inhibitors: potential of targeting calcium mobilization in immunosuppression. Proc Natl Acad Sci U S A. 2004;101:8969-8974.
16. Wu X, Ding S, Ding Q, Gray NS, Schultz PG. Small molecules that induce cardiomyogenesis in embryonic stem cells. J Am Chem Soc. 2004;126:1590-1591.
17. Charest PG, Terrillon S, Bouvier M. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep. 2005;6:334-340.
18. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103:11473-11478.
19. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003;4:463-476.
20. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005; 3:e128.
21. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol. 2005;12:385-395.
22. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:892-897.
23. Robson JM, Keele CA. Recent Advances in Pharmacology. London, England: J&A Churchill; 1956.
24. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47:1-9.
25. Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, de Silva H, Franke Y, Guan B, Heuer T, Hung T, Keegan K, Lee JM, Manne V, O'Brien C, Parry D, Perez-Villar JJ, Reddy RK, Xiao H, Zhan H, Cockett M, Plowman G, Fitzgerald K, Costa M, Ross-Macdonald P. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 2005;7:325-336.
26. Dempsey CM, Mackenzie SM, Gargus A, Blanco G, Sze JY. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics. 2005;169:1425-1436.
27. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, Stanley EF, McCourt P, Cutler SR, Roy PJ. A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature. 2006;441:91-95.
28. Rohde CB, Zeng F, Gonzalez-Rubio R, Angel M, Yanik MF. Microfluidic system for on-chip high-throughput whole-animal sorting and screening at subcellular resolution. Proc Natl Acad Sci U S A. 2007; 104:13891-13895.
29. Wells WA. High-throughput worms: NemaPharm, Inc. Chem Biol. 1998; 5:R147-R148.
30. Kokel D, Li Y, Qin J, Xue D. The nongenotoxic carcinogens naphthalene and para-dichlorobenzene suppress apoptosis in Caenorhabditis elegans. Nat Chem Biol. 2006;2:338-345.
31. Manev H, Dimitrijevic N, Dzitoyeva S. Techniques: fruit flies as models for neuropharmacological research. Trends Pharmacol Sci. 2003;24:41-43.
32. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, Warren ST. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008;4:256-263.
33. Bier E, Bodmer R. Drosophila, an emerging model for cardiac disease. Gene. 2004;342:1-11.
34. MacRae CA, Peterson RT. Zebrafish-based small molecule discovery. Chem Biol. 2003;10:901-908.
35. Peterson RT, Link BA, Dowling JE, Schreiber SL. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci U S A. 2000;97:12965-12969.
36. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev. 2005;4:35-44.
37. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004;95:459-470.
38. Fishman MC, Stainier DY. Cardiovascular development: prospects for a genetic approach. Circ Res. 1994;74:757-763.
39. Glickman NS, Yelon D. Cardiac development in zebrafish: coordination of form and function. Semin Cell Dev Biol. 2002;13:507-513.
40. Hsu CH, Wen ZH, Lin CS, Chakraborty C. The zebrafish model: use in studying cellular mechanisms for a spectrum of clinical disease entities. Curr Neurovasc Res. 2007;4:111-120.
41. Weinstein B. Vascular cell biology in vivo: a new piscine paradigm? Trends Cell Biol. 2002;12:439-445.
42. Weinstein BM, Stemple DL, Driever W, Fishman MC. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med. 1995;1:1143-1147.
43. Zhong TP, Rosenberg M, Mohideen MA, Weinstein B, Fishman MC. Gridlock, an HLH gene required for assembly of the aorta in zebrafish. Science. 2000;287:1820-1824.
44. Hong CC, Peterson QP, Hong JY, Peterson RT. Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. Curr Biol. 2006;16:1366-1372.
45. Peterson RT, Shaw SY, Peterson TA, Milan DJ, Zhong TP, Schreiber SL, MacRae CA, Fishman MC. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol. 2004;22:595-599.
46. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447:1007-1011.
47. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4:33-41.
48. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-regulated transgenic zebrafish model with conditional mycinduced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2005;102:6068-6073.
49. Le X, Langenau DM, Keefe MD, Kutok JL, Neuberg DS, Zon LI. Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish. Proc Natl Acad Sci U S A. 2007; 104:9410-9415.
50. Asakawa K, Kawakami K. Targeted gene expression by the Gal4-UAS system in zebrafish. Dev Growth Differ. 2008;50:391-399.
51. Esengil H, Chang V, Mich JK, Chen JK. Small-molecule regulation of zebrafish gene expression. Nat Chem Biol. 2007;3:154-155.
52. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Amacher SL. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol. 2008;26:702-708.
53. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol. 2008;26:695-701.
54. Foley JE, Yeh JR, Maeder ML, Reyon D, Sander JD, Peterson RT, Joung JK. Rapid mutation of endogenous zebrafish genes using zinc finger nucleases made by oligomerized pool engineering (OPEN). PLoS ONE. 2009; 4:e4348.
55. Douglas SA, Ohlstein EH, Johns DG. Techniques: cardiovascular pharmacology and drug discovery in the 21st century. Trends Pharmacol Sci. 2004;25:225-233.
56. Li Z, Yan Y, Powers EA, Ying X, Janjua K, Garyantes T, Baron B. Identification of gap junction blockers using automated fluorescence microscopy imaging. J Biomol Screen. 2003;8:489-499.
57. Min J, Kyung Kim Y, Cipriani PG, Kang M, Khersonsky SM, Walsh DP, Lee JY, Niessen S, Yates JR III, Gunsalus K, Piano F, Chang YT. Forward chemical genetic approach identifies new role for GAPDH in insulin signaling. Nat Chem Biol. 2007;3:55-59.
58. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation. 2003;107:1355-1358.
59. Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today. 2000;5:294-300.
60. Geysen HM, Schoenen F, Wagner D, Wagner R. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nat Rev. 2003;2:222-230.
61. Tan DS. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005;1:74-84.
62. Walters WP, Namchuk M. Designing screens: how to make your hits a hit. Nat Rev. 2003;2:259-266.
63. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004;432:855-861.
64. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 2000;287:1964-1969.
65. Shelat AA, Guy RK. The interdependence between screening methods and screening libraries. Curr Opin Chem Biol. 2007;11:244-251.
66. Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev. 2003;2:369-378.
67. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci. 2003;43:218-227.
68. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450:1001-1009.
69. Whitty A, Kumaravel G. Between a rock and a hard place? Nat Chem Biol. 2006;2:112-118.
70. Sleno L, Emili A. Proteomic methods for drug target discovery. Curr Opin Chem Biol. 2008;12:46-54.
71. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protocols. 2006;1:2650-2660.
72. Ong SE, Schenone M, Margolin AA, Li X, Do K, Doud MK, Mani DR, Kuai L, Wang X, Wood JL, Tolliday NJ, Koehler AN, Marcaurelle LA, Golub TR, Gould RJ, Schreiber SL, Carr SA. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009;106:4617-4622.
73. Gruhler A, Olsen JV, Mohammed S, Mortensen P, Faergeman NJ, Mann M, Jensen ON. Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway. Mol Cell Proteomics. 2005;4:310-327.
74. Lemeer S, Jopling C, Gouw J, Mohammed S, Heck AJ, Slijper M, den Hertog J. Comparative phosphoproteomics of zebrafish Fyn/Yes morpholino knockdown embryos. Mol Cell Proteomics. 2008;7:2176-2187.
75. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fassler R, Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008;134:353-364.
76. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, Davis RW. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet. 1999;21:278-283.
77. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004;116:121-137.
78. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, Fung E, Proctor M, Shokat KM, Zhang C, Davis RW, Giaever G, StOnge RP, Nislow C. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol. 2008;4:498-506.
79. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-1935.
80. Lamb J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer. 2007;7:54-60.
81. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25:197-206.
82. Peterson RT. Chemical biology and the limits of reductionism. Nat Chem Biol. 2008;4:635-638.